Pharmaceutical

Lilly drops osteoporosis pipeline drug

August 18, 2009
J.K. Wall
Eli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating the company’s attempts to find revenue before losing patent protection on its bestseller.
More

Lilly pays $224,000 to area doctors

August 17, 2009
 IBJ Staff
It’s no secret that Eli Lilly and Co. is the biggest private employer in the Indianapolis area. But Lilly also supplemented the incomes of a few dozen local doctors — to the tune of more than $224,000 in just the first quarter.
More

Lilly's Effient launch just one of its many challengesRestricted Content

August 3, 2009
Greg Andrews
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
More

Arcadia hopes health care reform means more revenueRestricted Content

August 3, 2009
J.K. Wall
The CEO of Indianapolis-based Arcadia Resources said the environment is perfect for his company's fast-growing DailyMed service.
More

Lilly cancels trials for experimental MS drug

July 28, 2009
J.K. Wall
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis after the drug failed to delay progression of the disease in trial patients.
More

Potential obesity breakthrough boosts Marcadia

July 20, 2009
J.K. Wall
Favorable article in prestigious journal could draw attention to Carmel biotech startup.
More

Drug industry funds Democrat-led panel on health care reformRestricted Content

July 20, 2009
J.K. Wall
The pharmaceutical industry—which for two decades has given twice as much in campaign donations to Republicans as Democrats—organized a panel composed mostly of Democrats this month in Indianapolis to argue its position on health care reform.
More

Professors go online to revolutionize drug discoveryRestricted Content

July 20, 2009
 IBJ Staff
Two chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and all over the world.
More

BREAKING: FDA approves Lilly blood-thinner prasugrel

July 10, 2009
J.K. Wall
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner, according to Bloomberg News.
More

Lilly cancer drug OK'd for new use

July 6, 2009
J.K. Wall
Eli Lilly and Co.'s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer for certain patients, Lilly announced today.
More

Profs trying to revolutionize drug discovery processRestricted Content

June 22, 2009
 IBJ Staff
Two chemistry professors at IUPUI are laboring to create the McDonald's of research laboratories—a model that's low-cost and can spread around the world.
More

With Byetta's sales stalled, Lilly unveils its own competitorRestricted Content

June 15, 2009
 IBJ Staff
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it's developing a potential competitor to Byetta all on its own.
More

Biotechnology firm boosts its protein bizRestricted Content

June 8, 2009
 IBJ Staff
Greenwood-based Elona Biotechnologies said it has created two subsidiaries to boost its biosimilar/biogeneric/follow-on protein business.
More

With pharma famine looming, Lilly relying on snack-size dealsRestricted Content

May 4, 2009
J.K. Wall
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year, Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
More

Indiana playing trailblazing role in drive to tailor pharmaceuticals to genetic makeup of individualsRestricted Content

April 13, 2009
Chris O'Malley
Indiana is becoming not only a hotbed of "pharmacogenomics" research, but also a trailblazer in finding practical ways to use it on the practitioner level.
More

In spite of criticism, Lilly saves livesRestricted Content

March 30, 2009
Steven J.
My wife, Becky, is alive today because of Lilly and its trial drug Enzastaurin, a great surgeon, and a terrific team of local doctors.
More

Logistics firm growsRestricted Content

February 16, 2009
MD Logistics has completed a coldstorage facility for pharmaceutical products in its hometown of Plainfield.
More

Biotech push may help offset generic competition; some analysts skepticalRestricted Content

February 2, 2009
J.K. Wall
Lilly executives want to make biotech their top focus.
More

Carmel startup lands $12M in venture capitalRestricted Content

January 19, 2009
Peter Schnitzler
Carmel startup Waterstone Pharmaceuticals Inc., which hopes to research drug components here and make them in China, has just raised $12 million in venture capital—despite the recession and a deep freeze in financial markets.
More

OBS Medical hopes to capture pharma's heartRestricted Content

January 19, 2009
J.K. Wall
The latest product to come out of Carmel-based OBS Medical may be just what the doctors ordered. The doctors working for major pharmaceutical companies, that is.
More

Targanta receives rescue line for drugRestricted Content

January 19, 2009
A former Eli Lilly and Co. antibiotic being developed in Indianapolis will live to try again. The company developing the drug, Massachusetts-based Targanta Therapeutics Inc., has agreed to be acquired by New Jersey-based The Medicines Co. for $42 million.
More

Lilly settles Zyprexa marketing suit for $1.4 billion

January 15, 2009
J.K. Wall
Indianapolis-based Lilly pleaded guilty to one violation of the Food, Drug and Cosmetic Act on Thursday and agreed to pay $1.42 billion to settle both that criminal charge as well as civil lawsuits in which it did not admit wrongdoing.
More

We must protect drug innovationRestricted Content

January 5, 2009
Thank you for shining light [in your Dec. 15 editorial] on the negative effects of unrestrained litigation by generic medicine marketers, aimed at breaking hard-won patents on branded prescription drugs.
More

Lilly eyes generic biotech drugsRestricted Content

January 5, 2009
Generic drugmakers have been the nemesis of companies like Eli Lilly and Co., but now the Indianapolis-based company and its peers want to get in the generic game themselves.
More

Lilly makes $6.5B acquisitionRestricted Content

December 29, 2008
J.K. Wall
Eli Lilly and Co. CEO John Lechleiter played a game of pharmaceutical poker with former Lilly Chief Financial Officer Jim Cornelius—and won.
More
Page  << 11 12 13 14 15 16 17 18 19 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am also a "vet" of several Cirque shows and this one left me flat. It didn't have the amount of acrobatic stunts as the others that I have seen. I am still glad that I went to it and look forward to the next one but I put Varekai as my least favorite.

  2. Looking at the two companies - in spite of their relative size to one another -- Ricker's image is (by all accounts) pretty solid and reputable. Their locations are clean, employees are friendly and the products they offer are reasonably priced. By contrast, BP locations are all over the place and their reputation is poor, especially when you consider this is the same "company" whose disastrous oil spill and their response was nothing short of irresponsible should tell you a lot. The fact you also have people who are experienced in franchising saying their system/strategy is flawed is a good indication that another "spill" has occurred and it's the AM-PM/Ricker's customers/company that are having to deal with it.

  3. Daniel Lilly - Glad to hear about your points and miles. Enjoy Wisconsin and Illinois. You don't care one whit about financial discipline, which is why you will blast the "GOP". Classic liberalism.

  4. Isn't the real reason the terrain? The planners under-estimated the undulating terrain, sink holes, karst features, etc. This portion of the route was flawed from the beginning.

  5. You thought no Indy was bad, how's no fans working out for you? THe IRl No direct competition and still no fans. Hey George Family, spend another billion dollars, that will fix it.

ADVERTISEMENT